Related Experiment Video
Updated: Jun 24, 2026

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
Published on: January 28, 2019
Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine
Insights
The American Academy of Pediatrics recommends routine rotavirus vaccination for infants using either the 3-dose RV5 (RotaTeq) or 2-dose RV1 (Rotarix) vaccine. Both vaccines are effective in preventing rotavirus gastroenteritis in infants.
Area of Science:
- Pediatrics
- Vaccinology
- Infectious Disease Prevention
Background:
- The 2007 American Academy of Pediatrics (AAP) statement on rotavirus gastroenteritis prevention is updated.
- Two rotavirus vaccines, RV5 (RotaTeq) and RV1 (Rotarix), are licensed for infant use in the United States.
Purpose of the Study:
- To provide updated recommendations for the routine immunization of infants in the United States with rotavirus vaccine.
- To outline the recommended schedules, contraindications, and precautions for rotavirus vaccine administration.
Main Methods:
- Review and synthesis of current evidence on rotavirus vaccines.
- Formulation of updated clinical recommendations by the American Academy of Pediatrics.
Main Results:
- The AAP recommends routine rotavirus vaccination for all infants.
- RV5 is a 3-dose series (2, 4, 6 months); RV1 is a 2-dose series (2, 4 months).
- No preference is stated between RV5 and RV1.
Conclusions:
- Routine rotavirus immunization is recommended for all infants in the United States.
- Specific age guidelines for vaccine administration (first dose 6-14.5 weeks, all doses by 8 months) are provided.
- Guidance on contraindications, precautions, and special circumstances is included.
Abstract:
This statement updates and replaces the 2007 American Academy of Pediatrics statement for prevention of rotavirus gastroenteritis. In February 2006, a live oral human-bovine reassortant rotavirus vaccine (RV5 [RotaTeq]) was licensed as a 3-dose series for use in infants in the United States. The American Academy of Pediatrics recommended routine use of RV5 in infants in the United States. In April 2008, a live, oral, human attenuated rotavirus vaccine (RV1 [Rotarix]) was licensed as a 2-dose series for use in infants in the United States. The American Academy of Pediatrics recommends routine immunization of infants in the United States with rotavirus vaccine. The American Academy of Pediatrics does not express a preference for either RV5 or RV1. RV5 is to be administered orally in a 3-dose series with doses administered at 2, 4, and 6 months of age; RV1 is to be administered orally in a 2-dose series with doses administered at 2 and 4 months of age. The first dose of rotavirus vaccine should be administered from 6 weeks through 14 weeks, 6 days of age. The minimum interval between doses of rotavirus vaccine is 4 weeks. All doses should be administered by 8 months, 0 days of age. Recommendations in this statement also address the maximum ages for doses, contraindications, precautions, and special situations for administration of rotavirus vaccine.
Related Concept Videos
Respiratory Syncytial Virus Disease
Poliomyelitis
Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
Bacterial Gastroenteritis
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Drug Dosing: Infants and Children
